Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 9,540 | 6-8周 | ||
50 mg | ¥ 12,400 | 6-8周 | ||
100 mg | ¥ 17,400 | 6-8周 |
Glesatinib hydrochloride 的其他形式现货产品:
产品描述 | Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC. |
体外活性 | Glesatinib hydrochloride (0.01, 0.1, 0.5, 1 μM) obviously enhances by several-fold the percentage of apoptotic cells in NSCLC H1299 cells. Glesatinib hydrochloride (0.01-5 μM; for 72 hours) causes a dose-dependent inhibition of cancer cell growth (IC50: 0.08 μM on NSCLC H1299 cells). Glesatinib hydrochloride has the cytotoxicity to P-gp overexpressing cancer cells KB-C2, SW620/Ad300, HEK293/ABCB1, and their parent cells KB-3-1, SW620, HEK293 cells with the IC50s fell between 5 and 10 μM [1]. Glesatinib hydrochloride (0-40 μM) stimulates the ATPase activity of P-gp transporters in a dose-dependent manner. Glesatinib hydrochloride (1, 3 μM; 120 mins) enhances the intracellular [3H]-Paclitaxel accumulation and inhibits [3H]-Paclitaxel efflux in cancer cell lines overexpressing P-gp [2]. |
体内活性 | Glesatinib hydrochloride (15 mg/kg/day; orally; 40 weeks) results in an obvious reduction in tumor size [1]. |
别名 | MGCD265 hydrochloride |
分子量 | 656.16 |
分子式 | C31H28ClF2N5O3S2 |
CAS No. | 1123838-51-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 28 mg/mL (42.67 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.524 mL | 7.6201 mL | 15.2402 mL | 38.1005 mL |
5 mM | 0.3048 mL | 1.524 mL | 3.048 mL | 7.6201 mL | |
10 mM | 0.1524 mL | 0.762 mL | 1.524 mL | 3.81 mL | |
20 mM | 0.0762 mL | 0.381 mL | 0.762 mL | 1.905 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Glesatinib hydrochloride 1123838-51-6 Tyrosine Kinase/Adaptors c-Met/HGFR Glesatinib Hydrochloride MGCD 265 Hydrochloride MGCD-265 Hydrochloride MGCD265 hydrochloride MGCD265 Hydrochloride Inhibitor inhibitor inhibit